Skip to main content
    P

    PetMed Express Inc (PETS)

    Official site

    HEALTHCARE • PHARMACEUTICAL RETAILERS • NASDAQ

    $0.90
    -0.04 (-4.52%)

    Market Cap: $20.90M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    PetMed Express Inc (PETS) Earnings: Report Dates and Results

    Updated Nov 10, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    PetMed Express (PETS) is expected to report earnings on Feb 3, 2027. In the quarter ended Sep 30, 2026, PetMed Express reported EPS of -$0.31, below the -$0.11 estimate. It beat the EPS estimate in 0 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    35%(14/40)
    Avg Surprise
    -88.61%

    Upcoming Estimates

    Reports Feb 3, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.16
    Range-$0.16 - -$0.16
    1 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.11-45.5%
    60d ago-$0.11-45.5%
    30d ago-$0.11-45.5%
    7d ago-$0.11-45.5%
    Current-$0.16
    Revenue Consensus
    N/A
    RangeN/A
    0 analysts
    Reports May 31, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.12
    Range$0.12 - $0.13
    3 analysts
    Revenue Consensus
    N/A
    RangeN/A

    Next Report

    PETS has an expected report date of Feb 3, 2027.

    PETS Earnings Call

    The latest PETS earnings call transcript on file is labeled 2025Q3.

    Read the 2025Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, PETS beat 14, missed 25 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $35.77M, down 19.4% from $44.36M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.31-$0.11-$0.11 - -$0.11-181.82%MissN/A10 up, 1 downNov 10, 2026$35.77M
    Jun 30, 2026-$0.28$0.12$0.12 - $0.12-333.33%MissN/A10 up, 0 downJul 27, 2026$41.02M
    Mar 31, 2026-$0.19-$0.18-$0.18 - -$0.18-5.56%MissN/A10 up, 1 downJun 2, 2026$42.82M
    Dec 31, 2025-$0.50-$0.06-$0.06 - -$0.06-733.33%MissN/A10 up, 1 downFeb 5, 2026$40.66M
    Sep 30, 2025-$0.56-$0.49N/A-14.29%Miss-609.1%10 up, 1 downDec 19, 2025$44.36M
    Jun 30, 2025-$0.06$0.21N/A-128.57%Miss-133.3%11 up, 0 downAug 11, 2025$51.18M
    Mar 31, 2025-$0.34-$0.04N/A-750.00%MissN/A10 up, 1 downJun 9, 2025$50.76M
    Dec 31, 2024-$0.03$0.01N/A-400.00%MissN/AN/A0 up, 0 downFeb 10, 2025$51.96M
    Sep 30, 2024$0.11-$0.05-$0.06 - -$0.05+320.00%BeatN/A20 up, 0 downNov 6, 2024$58.04M
    Jun 30, 2024$0.18-$0.09-$0.12 - -$0.06+300.00%Beat+80.0%20 up, 0 downAug 6, 2024$66.21M
    Mar 31, 2024-$0.25-$0.07-$0.07 - -$0.07-257.14%MissN/A10 up, 0 downApr 15, 2024$59.53M
    Dec 31, 2023-$0.10-$0.01-$0.03 - $0.01-900.00%Miss-600.0%20 up, 0 downFeb 8, 2024$65.32M
    Sep 30, 2023$0.00$0.09-$0.01 - $0.18-103.78%Miss-102.0%20 up, 0 downOct 30, 2023$71.00M
    Jun 30, 2023$0.10$0.07$0.06 - $0.09+42.86%Beat-33.3%30 up, 2 downJul 31, 2023$78.24M
    Mar 31, 2023-$0.25$0.14$0.10 - $0.20-278.57%Miss-183.3%30 up, 1 downMay 22, 2023$53.40M
    Dec 31, 2022$0.02$0.17$0.17 - $0.22-88.24%Miss-90.5%30 up, 0 downFeb 6, 2023$58.87M
    Sep 30, 2022$0.17$0.26$0.22 - $0.30-34.62%Miss-45.2%30 up, 0 downNov 7, 2022$65.26M
    Jun 30, 2022$0.15$0.23$0.21 - $0.30-34.78%Miss-34.8%30 up, 1 downJul 25, 2022$70.04M
    Mar 31, 2022$0.30$0.28$0.24 - $0.29+7.14%Beat-11.8%30 up, 1 downMay 9, 2022$64.87M
    Dec 31, 2021$0.21$0.32$0.32 - $0.35-34.38%Miss-44.7%20 up, 0 downJan 24, 2022$60.72M
    Sep 30, 2021$0.31$0.35$0.34 - $0.35-11.43%Miss-26.2%2N/AOct 25, 2021$67.39M
    Jun 30, 2021$0.23$0.35$0.33 - $0.38-34.29%Miss-41.0%2N/AJul 26, 2021$79.31M
    Mar 31, 2021$0.34$0.40$0.39 - $0.41-15.00%Miss-2.9%2N/AMay 3, 2021$66.05M
    Dec 31, 2020$0.38$0.38$0.37 - $0.380.00%In line+11.8%2N/AJan 19, 2021$60.72M
    Sep 30, 2020$0.42$0.40$0.37 - $0.42+5.00%Beat+27.3%2N/AOct 26, 2020$75.44M
    Jun 30, 2020$0.39$0.40$0.33 - $0.46-2.50%Miss+50.0%2N/AJul 20, 2020$96.20M
    Mar 31, 2020$0.35$0.29$0.23 - $0.35+20.69%Beat+9.4%2N/AMay 4, 2020$74.29M
    Dec 31, 2019$0.34$0.30$0.27 - $0.32+13.33%Beat-10.5%2N/AJan 21, 2020$59.91M
    Sep 30, 2019$0.33$0.26$0.22 - $0.31+26.92%Beat-36.5%3N/AOct 21, 2019$69.94M
    Jun 30, 2019$0.26$0.42$0.30 - $0.62-38.10%Miss-58.1%3N/AJul 22, 2019$79.99M
    Mar 31, 2019$0.32$0.46$0.40 - $0.53-30.43%Miss-36.0%3N/AMay 6, 2019$64.56M
    Dec 31, 2018$0.38$0.48$0.47 - $0.49-20.83%Miss-13.6%3N/AJan 22, 2019$60.07M
    Sep 30, 2018$0.52$0.50$0.49 - $0.51+4.00%Beat+20.9%4N/AOct 22, 2018$71.40M
    Jun 30, 2018$0.62$0.63$0.61 - $0.64-1.59%Miss+37.8%5N/AJul 23, 2018$87.39M
    Mar 31, 2018$0.50$0.47$0.44 - $0.53+6.38%Beat+35.1%4N/AMay 7, 2018$67.32M
    Dec 31, 2017$0.44$0.31$0.26 - $0.37+41.94%Beat+83.3%4N/AJan 22, 2018$60.11M
    Sep 30, 2017$0.43$0.30$0.25 - $0.35+43.33%Beat+79.2%5N/AOct 23, 2017$66.71M
    Jun 30, 2017$0.45$0.38$0.33 - $0.40+18.42%Beat+40.6%4N/AJul 24, 2017$79.66M
    Mar 31, 2017$0.37$0.26N/A+42.31%Beat+37.0%N/AN/AMay 8, 2017$63.03M
    Dec 31, 2016$0.24$0.25N/A-4.00%Miss0.0%N/AN/AJan 23, 2017$52.87M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Mar 31, 2026 was -$1.31, after -$0.08 the year before. It was $1.17 for the year ended Mar 31, 2017, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Mar 31, 2026-$1.31N/A
    Mar 31, 2025-$0.08N/A
    Mar 31, 2024-$0.25-381.6%
    Mar 31, 2023$0.09-91.4%
    Mar 31, 2022$1.05-31.4%
    Mar 31, 2021$1.53+19.5%
    Mar 31, 2020$1.28-30.4%
    Mar 31, 2019$1.84N/A
    Mar 31, 2018$1.82+55.6%
    Mar 31, 2017$1.17N/A

    Earnings Calls

    The 4 most recent earnings calls are listed below; the latest, 2025Q3 for the period ended Sep 30, 2025, runs about 3,400 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2025Q3Sep 30, 20253,4446
    2025Q2Jun 30, 20252,6955
    2025Q1Mar 31, 20253,5645
    2024Q4Dec 31, 20244,5366

    2025Q3 Earnings Call

    Opening remarks

    Reed Anderson Host Thank you, and welcome to the PetMed Express fiscal third quarter 2025 earnings conference call. Certain information included during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Securities Exchange Act of 1934 as amended that may involve a number of risks and uncertainties. These statements are based on our beliefs as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties and assumptions. Actual results could differ materially from those projected. There can be no assurance that any forward-looking results will occur or be realized and nothing contained in this presentation is or should be relied upon as a representation or warranty as to any future matters, including any matter in respect of the operations or business or financial condition of PetMed. PetMed undertakes no obligation to update publicly these forward-looking statements based on subsequent events, except as may be required by applicable law, regulation or other competent legal authority. We've identified various risk factors associated with our operations in our most recent annual report and other filings with the Securities and Exchange Commission. Now, let me turn the call over to our CEO and President, Sandra Campos.

    Sandra Campos CEO Thank you, Reed, and welcome to everyone joining our call this afternoon. Following my remarks, Robyn will provide a detailed overview of our financial results, after which we'll open the lines for your questions. Over the past nine months, I have emphasized that our focus remains steadfast on the strategic initiatives pivotal to repositioning PetMed and PetCareRx for long-term success. I have clearly outlined our vision to position PETS as a leader in consumer pet healthcare. While we're still in the early stages of this transformation and have much more work ahead, I am pleased to report that we have made significant progress in validating our strategic direction. We're confident that the actions we're taking will drive differentiation and sustainable growth. Our highest priority has been to return the company to profitability. We achieved this by implementing cost-cutting measures and consolidation strategies to integrate PetCareRx operations into the PetMed organization, targeting $5 million in annualized savings, and we remain on track to meet this milestone. For this quarter Q3, we achieved $2 million in adjusted EBITDA representing a $1.1 million improvement year-over-year while lowering G&A expenses by $2.6 million, compared to last year. As we continue to execute our turnaround strategy, we remain committed to driving shareholder value through growing our customer base, operational discipline, and financial efficiency. At PETS, we serve three core communities. First, our pet parents.

    Frequently Asked Questions About PETS

    When is PetMed Express's next earnings date?

    PetMed Express's next earnings report is expected for Feb 3, 2027.

    Did PETS beat earnings estimates last quarter?

    No. PetMed Express reported EPS of -$0.31 for the quarter ended Sep 30, 2026, below the -$0.11 estimate by 181.82%.

    What EPS do analysts expect from PETS next quarter?

    The consensus EPS estimate for PetMed Express for the quarter ending Dec 31, 2026 is -$0.16 from 1 analyst, with estimates from -$0.16 to -$0.16.

    How often does PETS beat earnings estimates?

    PetMed Express beat the EPS estimate in 0 of the last 8 quarters, with an average surprise of -318.36%.